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We conducted a randomized, double-blind, placebo-
controlled trial to assess the atrophogenicity of tacrolimus
ointment. In a combined group of atopic dermatitis
patients (n J 14) and healthy volunteers (n J 12), 0.3%
tacrolimus, 0.1% tacrolimus, betamethasone-valerate,
and a vehicle control were applied in a randomized order
to nonsymptomatic, 4 cm H 4 cm regions of abdominal
skin. After 7 d of treatment under occlusion, the carboxy-
and amino-terminal propeptides of procollagen I (PICP,
PINP) and the amino-terminal propeptide of procollagen
III (PIIINP) were measured from suction blister fluid
with specific radioimmunoassays. In addition, ultrasound
measurements of skin thickness were taken. Betame-
thasone-treated areas showed median PICP, PINP, and
Atopic dermatitis is characterized by episodes of intensepruritus, lichenification, and severely dry skin, and asusceptibility to cutaneous infections (Merk, 1991). Onlycorticosteroids are available for topical treatment of thedisease. Although topical corticosteroids are generally
well tolerated, they commonly cause skin atrophy and less frequently
hypopigmentation, secondary infections, and acne (Boguniewicz and
Leung, 1996). The atrophogenicity of topical corticosteroids limits
their use on areas of skin that are thin, such as the face and neck and
flexure regions, and some patients become resistant to corticosteroid
treatment (Reitamo et al, 1986); thus, a treatment alternative is
greatly needed.
Tacrolimus (FK506) is an effective and well-tolerated immuno-
suppressant in solid organ transplantation (Fung et al, 1996) and in
psoriasis (European FK506 Multicentre Psoriasis Study Group, 1996).
This macrolide has a similar mode of action to cyclosporine (Goto
et al, 1991), but unlike cyclosporine, tacrolimus can penetrate skin to
effect local immunosuppression when applied topically. Case studies
have shown clinical improvement of atopic dermatitis with topical
tacrolimus treatment (Nakagawa et al, 1994). In a recent multicentre
trial with over 200 patients, 0.03%, 0.1%, and 0.3% tacrolimus ointment
significantly improved atopic dermatitis in comparison with a vehicle
control (Ruzicka et al, 1997). Although skin atrophy was not observed,
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PIIINP concentrations of 17.0%, 17.6%, and 39.5% of
the vehicle control at the end of the treatment period,
respectively, whereas the 0.1% and 0.3% tacrolimus-
treated areas showed median concentrations of µ100%
of the vehicle control (p < 0.001). Betamethasone was
also the only treatment to reduce skin thickness; the
median decrease in skin thickness was 7.4% relative to
0.1% tacrolimus, 7.1% relative to 0.3% tacrolimus, and
8.8% relative to the vehicle control (p < 0.01). Results
for atopic dermatitis patients and healthy volunteers were
similar. These findings suggest that tacrolimus does not
cause skin atrophy. Key words: atrophy/PICP/PINP/skin.
J Invest Dermatol 111:396–398, 1998
the treatment period of 3 wk was too short for clinical signs of atrophy
to become apparent.
The objective of this study was to assess whether tacrolimus ointment
is atrophogenic. This was done by measuring collagen expression in a
combined group of atopic dermatitis patients and healthy volunteers
after 1 wk of exposure to 0.1% tacrolimus, 0.3% tacrolimus, betame-
thasone-valerate, or a vehicle control on defined areas of symptom-
free abdominal skin. Collagen synthesis was assessed by measuring the
amino- and carboxy-terminal propeptides of procollagen I (PINP and
PICP, respectively) and the amino-terminal propeptide of procollagen
type III (PIIINP) at the treated sites (Autio, 1994). In addition to the
assessment of collagen expression, the treated sites were evaluated for
skin thickness using ultrasound technology. The study was carried out
between 24 September 1996 and 3 February 1997.
MATERIALS AND METHODS
Study design This was a phase II, randomized, double-blind study carried
out at Helsinki University Central Hospital, Helsinki, Finland. The study was
conducted in compliance with good clinical practice guidelines (Committee for
Proprietary Medicinal Products, Commission of the European Communities).
Subjects Male and female subjects, 18–60 y of age, were eligible for entry.
All subjects were required to give informed consent, and the study was approved
by the local ethics committee. Atopic dermatitis patients were required to have
a confirmed diagnosis of moderate to severe atopic dermatitis according to the
criteria of Hanifin and Rajka (1980), and to have a nonsymptomatic region of
abdominal skin of at least 350 cm2.
Intervention Four abdominal regions of 4 cm 3 4 cm were selected for
each atopic dermatitis patient and healthy volunteer. An investigator applied
the four study ointments to the selected abdominal regions. The ointments
were 0.1% and 0.3% tacrolimus, betamethasone-valerate (Betnovat, Glaxo
Pharmazeutica GmbH, the ointment contained 0.1% betamethasone), and a
vehicle control (the tacrolimus ointment base). Treatment was done under
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Table I. Demographic and baseline characteristics of atopic
dermatitis patients and healthy volunteers
Atopic dermatitis patients Healthy volunteers
(n 5 14) (n 5 12)
Demographics
Mean age (y)a 24.9 6 10.4 37.4 6 11.6
Number of female 3 (21.4%) 5 (41.7%)
participants
Number of white 14 (100.0%) 12 (100.0%)
participants
Disease severity at
baselineb
Mild 1 (7.1%) -
Moderate 9 (64.3%) -
Severe 4 (28.6%) -
a Mean 6 SD.
b The extent, course (duration of active disease in a given year), and intensity were
each graded on a scale of 0–3 and summed: mild (3–4), moderate (5–7), severe (8–9).
Table II. Median normalized valuesb for PICP, PINP, and
PIIINPb after 7 d of treatment were reduced only in the
betamethasone ointment treatment arm (n J 25)
0.1% 0.3% Betamethasone p valuea
tacrolimus tacrolimus
PICP
Median 96.2 97.7 17.0 ,0.001
Lower quartile 83.4 78.5 9.1
Upper quartile 149.7 114.3 25.9
PINP
Median 115.0 93.8 17.6 ,0.001
Lower quartile 88.2 76.5 10.9
Upper quartile 154.0 112.5 26.1
PIIINP
Median 110.5 97.1 39.5 ,0.001
Lower quartile 68.6 81.6 15.5
Upper quartile 174.4 157.1 88.1
a Friedman’s test for overall treatment effect.
b For each subject and each active treatment, a normalized value was obtained by dividing
the value for a given active treatment by the value obtained for vehicle treatment and
multiplying the result by 100 to obtain a percentage.
c PICP, carboxy-terminal propeptide of procollagen I; PINP, amino-terminal peptide of
procollagen I; PIIINP, amino-terminal propeptide of procollagen III.
occlusion. Application of the ointments was done on the day of entry, and 3–
4 d later, and the occlusive bandages were removed after 1 wk. No concurrent
treatment, other than emollients or bath oil, was allowed during the study.
Treatment assignment and blinding An unique document that stated the
arrangement of the four ointments on the four abdominal patches was computer
generated for each subject by the sponsor. To maintain blinding, the investigators
who applied the ointments were different from those who carried out the
assessments.
Assessments After 1 wk of treatment under occlusion, a disposable suction
blister device (Ventipress Oy, Lappeenranta, Finland) was used to draw interstitial
fluid between the epidermis and the dermis at the treated areas (Kiistala, 1968).
PICP, PINP, and PIIINP concentrations were measured from the aspirated
interstitial fluid samples by specific radioimmunoassays (Orion Diagnostica, SF-
90460, Oulunsalo, Finland). Skin thickness (the distance between the stratum
corneum to lower dermis) was measured with a high-frequency ultrasound
device (DUB20-S, Taberna Pro Medicum, Lu¨neburg, Germany) (Tan et al,
1982). The skin thickness of any particular region was the average of four
measurements taken 1 mm apart from each other.
At baseline, patients with atopic dermatitis were assessed for overall disease
severity as described by Rajka and Langeland (1989).
Statistical analysis PICP, PINP, and PIIINP values for each subject and
each active treatment were normalized relative to the vehicle control by dividing
the value for a given active treatment by the value obtained for the vehicle
control and multiplying the result by 100 to obtain a percentage. This conversion
was carried out to reduce baseline differences among subjects. For the ultrasound
measurements, absolute values were used. For both assessments, the medians of
Figure 1. Concentrations of PICP, PINP, and PIIINP after 1 wk of
treatment with 0.1% tacrolimus, 0.3% tacrolimus, betamethasone, or
a vehicle control showed reduced values only for betamethasone-treated
sites (n J 25). The middle line of each box represents the median value. The
top and bottom lines of each box represent the upper and lower quartiles,
respectively, and the upper and lower bars represent the 90% and 10% limits.
The closed circles are individual values. 0.1% Tac, 0.1% tacrolimus; 0.3% Tac,
0.3% tacrolimus; Bet, betamethasone ointment; Veh, vehicle (the tacrolimus
ointment base).
paired differences were estimated using the method of averaging differences
(Gardner and Altman, 1989). Overall treatment comparisons were carried out
with Friedman’s test, and pair-wise comparisons were carried out with the
Wilcoxon rank sum test (Gardner and Altman, 1989; Sprent, 1989).
Sample size No formal sample size calculation was performed because the
distribution of the data could not be predicted. The choice of 22 subjects in
the study protocol was based on practical considerations. This sample size was
determined to permit a power of 80% to detect a difference of 20% in a two-
sided statistical test with unpaired observations (for comparison of two ointments
with a significance level of 0.05) when a normal distribution was assumed.
RESULTS
Subjects A total of 28 subjects were screened: 16 atopic dermatitis
patients and 12 healthy volunteers. Two atopic dermatitis patients were
screened but not randomized: one did not meet selection criteria and
the other had withdrawn consent. Thus, 26 subjects were included in
the intent-to-treat population. There were no withdrawals during the
study. Except for one subject who did not contribute data for the
collagen assessments, there were no protocol deviations. Demographic
characteristics were similar for atopic dermatitis patients and healthy
volunteers (Table I).
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Procollagen concentrations The betamethasone treatment arm
was the only one to show significant decreases in PICP, PINP, and
PIIINP after 7 d of treatment (p , 0.001, Friedman’s test); PICP and
PINP concentrations were reduced to about one-fourth of the vehicle
control and PIIINP was reduced to less than half of the vehicle control
(Fig 1 and Table II). Sites treated with 0.1% and 0.3% tacrolimus
showed normalized values close to 100% for the collagen expression
markers. Pair-wise comparisons confirmed significantly reduced nor-
malized PICP, PINP, and PIIINP concentrations in the betamethasone
arm (p , 0.001 for each comparison with 0.1% or 0.3% tacrolimus,
Wilcoxon matched pairs signed test), and no significant difference
between the tacrolimus arms. Separate analyses of atopic dermatitis
patients and healthy volunteers showed similar results (data not shown).
Skin thickness Betamethasone was also the only treatment to reduce
skin thickness. The median decrease in skin thickness was 7.4% relative
to 0.1% tacrolimus (p 5 0.005), 7.1% relative to 0.3% tacrolimus (p 5
0.008), and 8.8% relative to the vehicle control (p , 0.001). The
differences between all other treatment pairs were not statistically
significant. Separate analyses of atopic dermatitis patients and healthy
volunteers showed similar results (data not shown).
DISCUSSION
This is the first trial to investigate whether topical tacrolimus has
atrophogenic properties in human subjects; however, previous animal
studies have suggested that topical tacrolimus is not atrophogenic. At
a concentration that gave comparable efficacy to the superpotent and
atrophogenic corticosteroid clobetasol-17-propionate (0.13%) in an
inflammatory reaction in pig skin, topical tacrolimus did not cause skin
atrophy (Meingassner and Stu¨tz, 1992). In a rat model, tacrolimus did
not reduce skin thickness, but 0.05% clobetasol propionate, 0.05%
clobetasol butyrate, 0.12% betamethasone valerate, and 0.5% prednisone
produced significant skin thinning under the same conditions (Hisatomi
et al, 1997).
Our findings on the effect of betamethasone ointment on collagen
expression in human skin are similar to those reported in the literature,
which suggests that our measurements are reliable. In healthy volunteers,
3 d of topical betamethasone application (without occlusion) decreased
PINP to 23% of normal and PIIINP to 31% of normal (Haapasaari
et al, 1996). Similarly, an earlier study reported an approximate 5%
decrease in skin thickness after 1 wk of betamethasone treatment under
occlusion (Dykes et al, 1988), which is similar to the approximate 7%
decrease observed in our study.
During the planning of this study, there was some concern that the
penetration qualities of skin in atopic dermatology patients and healthy
volunteers might differ. Thus, the data were analyzed for the combined
group and separately. The statistical results from both groups of subjects
and the combined group were similar, which suggests that combining
these data for a single analysis was appropriate. To assess drug penetra-
tion, we conducted patch tests with dinitrochlorobenzene on all four
abdominal areas in a small subgroup of healthy volunteers who had
been earlier sensitised to dinitrochlorobenzene (data not shown) (Niwa
et al, 1982; Reitamo et al, 1989). In three of the four subjects with
positive dinitrochlorobenzene patch test reactions, areas treated with
0.1% tacrolimus, 0.3% tacrolimus, or betamethasone showed reduced
patch test reactions, indicating that there was local immunosuppression
at these sites (i.e., adequate drug penetration).
Type I collagen makes up 80%–85% of all skin collagen, whereas
type III comprises up to 10%–15%. These collagens are synthesized in a
precursor form that includes one additional amino- and carboxyterminal
propeptide. When a collagen molecule is formed, these propeptides
are cleaved off. Thus, the concentration of these propeptides in situ is
proportional to the amount of local collagen expression in skin (Autio,
1994). It has been known for a long time that topical corticosteroids
reduce collagen synthesis (Dykes and Marks, 1979). The reduction in
collagen synthesis is widely accepted as a molecular manifestation of
the process of skin atrophy; however, they are not the same thing.
Skin atrophy is a clinical phenomenon. To assess whether tacrolimus
is associated with a risk of skin atrophy, it should be further evaluated
over a long period in a clinical setting.
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